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Abstract
The initiation of transcription and replication of influenza A virus requires the 5' and 3' ends of
vRNA. Here, the role of segment-specific non-coding sequences of influenza A virus on viral RNA
synthesis was studied. Recombinant viruses, with the nonstructural protein (NS) segment-specific
non-coding sequences replaced by the corresponding sequences of the neuraminidase (NA)
segment, were characterized. The NS and NA vRNA levels in cells infected with these mutants
were much higher than those of the wild type, whereas the NS and NA mRNA levels of the mutants
were comparable to the wild-type levels. By contrast, the PB2 vRNA and mRNA levels of all the
tested viruses were similar, indicating that vRNA with heterologous segment-specific non-coding
sequences was not affected by the mutations. The observations suggested that, with the
cooperation between the homologous 5' and 3'segment-specific sequences, the introduced
mutations could specifically enhance the replication of NA and NS vRNA.
Background
The genome of influenza A virus contains 8 RNA segments
of negative polarity [1]. Each virion RNA (vRNA) can be
used as a template for transcription and replication to gen-
erate viral mRNA and complementary RNA (cRNA),
respectively. cRNA is a faithful complementary copy of
vRNA and is used as a template for vRNA synthesis. By
contrast, the transcription of the viral mRNA is terminated
at a track of uridines (U) which is about 17 nucleotides
away from the 5' end of the vRNA template [2,3] and the
polymerase then starts to polyadenlyate the mRNA by
reiteratively copying of the U-track [4,5]. It is generally
believed that there is a control mechanism to regulate the
polymerase's transcriptase and replicase activities [6].
However, recent studies have suggested an alternative
hypothesis that such switching mechanism might not
exist [7-10].
Sequence analyses of all the vRNA segments revealed that
the first 12 and 13 nucleotides at their 3' and 5' ends are
highly conserved [11]. Extensive studies on these
sequences indicated that these regions are the promoter
for transcription and replication. These sequences were
shown to be involved in the viral polymerase binding [12-
14], cap-snatching [14,15], and transcription initiation
[16,17]. The 5' and 3' ends of each vRNA are partially
inverted complementary and can form a corkscrew struc-
ture that is known to be critical for the above biological
processes [6]. Within these conserved sequences, there is a
single natural variation (U or C) at the 4th residue of the 3'
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end [11]. Of all the vRNA segments, the polymerase seg-
ments (PB2, PB1 and PA) invariably carry a C residue at
this position (C4), whereas most of the other segments
contain a U residue at this position (U4). Mutagenic stud-
ies of this polymorphic site suggested that this nucleotide
variation might modulate viral transcription and replica-
tion [18,19]. Adjacent to the universally conserved
regions, each vRNA segment contains additional non-cod-
ing sequences at its 5' and 3' regions. The lengths and
sequences of these non-coding sequences are segment
specific. Growing evidences have supported the hypothe-
sis that these sequences are parts of the viral RNA packag-
ing signals [20-24]. In addition, disrupting the NA
segment-specific sequences were shown to have effects on
viral RNA synthesis [25-27], indicating these segment spe-
cific sequences might modulate viral RNA synthesis.
Findings
In this study, we replaced the 5' and 3' NS segment-spe-
cific non-coding sequence with the corresponding
sequences of the NA to investigate the role of segment-
specific sequences on viral transcription and replication.
An A/WSN/33 (H1N1) mutant with the above mutation
(hereafter called the NSNA mutant, see Additional file 1)
was generated by reverse genetics techniques [28]. The
recombinant virus was titrated by standard plaque assays
and the introduced mutations were confirmed by
sequencing. The NSNA mutant was viable, but its maxi-
mum viral titre was about 1 log unit lower than that of the
parental strain (A/WSN/33) (Fig. 1). This agreed with the
previous findings that the vRNA segment-specific
sequences are attenuated [26,27].
As the NA and NS vRNA of the mutant shared the identi-
cal segment-specific non-coding sequences, the effects of
the mutations on the transcription and replication of
these two segments were determined. Quantitative RT-
PCR assays specific for the vRNA and mRNA of these seg-
ments were developed for the study. In addition, mRNA
and vRNA derived from the PB2 segment were also quan-
titated by real-time PCR assays as controls. Total RNA
from cells infected with the wild-type or the NSNA virus at
an MOI of 2 was harvested at every two-hour intervals.
The RNA samples were then converted into cDNA by
using oligo dT20 or by vRNA-specific primer. The cDNA
derived from the viral mRNA or vRNA was then tested by
corresponding gene-specific quantitative assays (Fig. 2).
As shown in the right panel of Fig. 2A, the level of NS
vRNA from cells infected with the NSNA mutant was sig-
nificantly higher than that of the wild type (~7.8 folds, p
= 0.002). By contrast, the level of NS mRNA was slightly
less than that of the wild type (Fig. 2B, right panel). Strik-
ingly, the NA vRNA level in cells infected with the NSNA
was also found to be about 2.5 folds higher than that of
the wild type (Fig. 2A, middle panel; P < 0.001), but the
NA mRNA levels of these viruses were statistically similar
to each other (Fig. 2B, middle panel, P > 0.05). The PB2
vRNA and mRNA levels of the mutant were similar to the
Growth properties of the wild type and NSNA mutants in MDCK cells Figure 1
Growth properties of the wild type and NSNA mutants in MDCK cells. (A) Quantitation of infectious progeny viral particles 
generated from infected cells by standard plaque assays. (B) Plaque morphologies of the wild type (WT) and NSNA mutant.Virology Journal 2008, 5:2 http://www.virologyj.com/content/5/1/2
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wild-type levels (Figs. 2A and 2B, left panels). These
results suggested that the introduced mutations specifi-
cally up-regulate the replication, but not transcription, of
the NA and NS segments. Interestingly, even the NS and
NA vRNA expression levels are enhanced in infected cells,
the NSNA mutant was shown to be attenuated. It is possi-
Quantitation of PB2, NA and NS vRNA (A) and mRNA (B) in cells infected with the wild-type (WT) or NSNA virus at different  postinfection time points Figure 2
Quantitation of PB2, NA and NS vRNA (A) and mRNA (B) in cells infected with the wild-type (WT) or NSNA virus at different 
postinfection time points. Uni-12 primer (0.2 ng/μl) [35] was used for the cDNA synthesis of vRNA, whereas oligo dT20 (25 
μM) was used to generated cDNA of viral mRNA. In a typical reverse transcription reaction, 0.5 μg of DNase-treated RNA 
sample was mixed with 1 μl of the corresponding primer, 4 μl of 5x first stand buffer, 2 μl of 0.1M dithiothreitol, and 1 μl of 10 
mM deoxyribonucleoside triphosphates (Strategene), 150 U of SuperScript II reverse transcriptase in a 20 μl reaction. For 
detecting NA and NS RNA species, RNase-treated cDNA was examined by 5'-nuclease-based assays in a 7300 Sequence 
Detection System (Applied Biosystems). Briefly, 5 μl of the corresponding diluted cDNA samples were mixed with 12.5 μl 
superMix-UDG (Invitrogen), 0.5 μl of Rox reference dye, 1 μl of 10 mM forward primer, 1 μl of 10 mM reverse primers, 1 μl 
of 10 mM probe and 4 μl of water. Reactions were first incubated at 50°C for 2 min, followed by 95°C for 10 min. Reactions 
were then thermal-cycled for 45 cycles (95°C for 15 sec, 56°C for 1 min). Primers used in the NA detection assay were 5'-
ACCGACCATGGGTGTCCTT-3' (corresponds to nt 870–888 of the NA cRNA) and 5'-GAAAATCCCTTTACTC-
CGTTTGC-3' (complementary to nt 998–1020 of the NA cRNA). Primer used in the NS detection assay were 5'-TACCT-
GCATCGCGCTACCTA-3' (corresponds to nt 277–296 of the NS cRNA) and 5'-ATGATCGCCTGGTCCATTCT-3' 
(complementary to nt 378–397 of the NS cRNA) were used. The probes used in the NA and NS assays were 5'-FAM-CGTC-
CCAAAGATGGA-NFQ-3' (corresponds to nt 950–964 of the NA cRNA; FAM, 6-carboxyfluorescein; NFQ, nonfluorescent 
quencher) and 5'-VIC-CACTGGTTCATGCTCA-NFQ-3' (corresponds to nt 327–342 of the NA cRNA; VIC, a proprietary 
dye), respectively. For the quantitation of PB2 RNA species, cDNA samples were amplified by using FastStart DNA Master 
SYBR Green I kit (Roche) in a LightCycler platform (Roche). In a typical reaction, 5 μl of RNase-treated cDNA was mixed with 
2 μl master mixtures, 1.6 μl of MgCl2, 1 μl of forward primer (5'-CCGCAGTTCTGAGAGGATTC-3', corresponds to nt 
2090–2109 of PB2 cRNA), 1 μl of reverse primer (5'-TCCGTTTCCGTTTCATTACC-3', complementary to nt 2226–2245 of 
the PB2 cRNA) and 1.6 μl of water. Reactions were first incubated at 95°C for 10 min, followed by a thermal-cycling (95°C for 
10 sec, 58°C for 5 sec, 72°C for 15 sec; 40 cycles). The specificities of the amplified products were all confirmed by melting 
curve analysis. In all the PCR assays, serially diluted plasmids containing the corresponding sequences were used as standard 
controls. All the data were derived from three independent assays. The levels of mRNA and vRNA from the studied mutants 
were analyzed by two-tails paired t-test.Virology Journal 2008, 5:2 http://www.virologyj.com/content/5/1/2
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ble that the introduced mutations would disturb other
virological processes, such as vRNA packaging [20-24].
It should be noted that the 4th residue at the 3' end of the
PB2, PB1 and PA vRNA segments in our studied strain is a
C. By contrast, all the other segments contain a U residue
at this position. Previous studies indicated that sequence
variations at this position would affect the viral transcrip-
tion and replication [19]. To eliminate the possibility that
the mutations in the NS vRNA would only affect those
vRNA segments with a "U4" promoter, an additional pair
of mutants was generated (Supplementary Fig. 1. All-U
and NSNA-U). The All-U and NSNA-U mutants were
genetically identical to the wild type and NSNA, respec-
tively, except all the vRNA segments of these mutants con-
tained a "C4" promoter. As shown in Fig. 3, quantitative
results derived from these two mutants were similar to
those observed from the wild type and NSNA mutant. Of
all the analyzed RNA species, only the NS and NA vRNA
levels of the NSNA-U mutants were statistically higher
than those of the All-U mutant (Fig 3A, right and middle
panels; P = 0.003 and 0.002, respectively). The NS and NA
vRNA levels in cells infected with the NSNA-U were 14.1
and 6.7 folds, respectively, higher that those of the All-U
mutant. By contrast, the NA mRNA level of NSNA-U
mutant was only comparable to that of the All-U (Fig. 3B,
middle panel) and the NS mRNA expression of NSNA-U
was reduced (Fig. 3B, right panel). The mutations had lit-
tle effects on PB2 vRNA and mRNA levels as expected
(Figs. 3A and 3B, left panels). These results confirmed our
observations that the mutations in NS segment could spe-
cifically up-regulate the NS and NA vRNA replications.
One of the possible mechanisms account for the elevation
of NS and NA vRNA levels is that the 5' and 3' segment-
specific regions would facilitate the initiation of vRNA
replication. This stimulating effect, however, might
require the presence of the 5' and 3' segment-specific
regions from homologous segments. As the NA and NS
vRNA segments in the NSNA and NSNA-U mutants had
the identical non-coding sequences, the availability of
compatible 5' ends for initiating NS and NA vRNA repli-
cations would be increased. This hypothesis is supported
by two of our observations. First, our data demonstrated
that the mutations had no effect on vRNA which has het-
erologous segment-specific sequences (i.e. PB2). In addi-
Quantitation of PB2, NA and NS RNA species in cells infected with the All-U or NSNA-U mutants at various postinfection  time points Figure 3
Quantitation of PB2, NA and NS RNA species in cells infected with the All-U or NSNA-U mutants at various postinfection 
time points. (A) PB2, NA and NS vRNA levels as indicated. (B) PB2, NA and NS mRNA levels as indicated. All the data were 
derived from three independent assays.Virology Journal 2008, 5:2 http://www.virologyj.com/content/5/1/2
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tion, our data showed that the transcription of the NA and
NS segments were not up-regulated. These agreed with
previous findings that the viral polymerase has to bind to
the 5' and 3' ends of the same vRNA template for mRNA
synthesis [12,29]. Thus, the increases of compatible ends'
populations would not   expected to have stimulating
effects on the NS and NA mRNA expressions. Interest-
ingly, the NS mRNA levels from the NSNA and NSNA-U
mutants in this study seemed to be less than that of the
corresponding controls (Figs. 2B and 3B, right panels). It
is possible that, due to the increase of the number of these
compatible ends in infected cells, the polymerase might
have less chance to bind to the ends of the same vRNA
template for transcription initiation.
If our hypothesis was correct, the cRNA productions of the
affected segments (NA and NS) were expected to be
enhanced in the same fashion. To test this hypothesis, we
used a primer extension assays to measure the cRNA levels
in infected cells. As both NS and NA vRNA segments of
the NSNA-U mutant were highly up-regulated (Fig. 3A),
we used NSNA-U and All-U mutants as the studied strains
in this semi-quantitative assay. Total RNA samples har-
vested at 8 and 24 hour post-infection were analyzed. We
selected the NA segment as the target because these two
mutants have the identical wild-type NA sequence. As
shown in Fig. 4, cRNA levels generated from the NSNA-U
were consistently higher then those of the All-U mutant.
At 24 hr postinfection, cells infected with the NSNA-U
had comparable mRNA and cRNA levels. By contrast, the
majority of positive-stranded RNA of the All-U mutant
was found to be mRNA. Agreed with our results from the
quantitative RT-PCR (Fig. 3), the vRNA level of the NSNA-
U was found to be much higher than the level of the All-
U mutant (Fig. 4). These results further supported our
findings that the 5' and the 3' segment-specific regions
derived from the homologous segments might have a
stimulatory effect on viral RNA replication. However, fur-
ther work is required to confirm this hypothesis and we
do not entirely exclude other hypotheses that might
explain the above findings. For example, it is possible that
the introduced mutations might also help the NS and NA
vRNA form stable secondary structure in trans, thereby
reducing the degradation rates of these vRNA [10]
In the early phase of viral infections, vRNP predominantly
synthesizes mRNA for viral protein synthesis [30]. This is
followed by an active phase of viral RNA replication. It
was previously proposed that the nascent NP expressed in
infected cells might stimulate viral RNA replication
[31,32]. Recent evidences have provided an alternative
hypothesis to explain this observation. Rather than stim-
ulating the viral RNA replication, free NP and viral
polymerase are proposed to protect nascent cRNA from
degradation by binding to these newly synthesized cRNA
transcripts [7,9,33]. The results from our current study
might also help to explain the dramatic increase of cRNA
levels in the late phase of viral infection. In the early phase
of infection, the amount of vRNA is low and the viral
polymerase is more likely to bind to the ends of the same
vRNA template for transcription (i.e. activate in cis). Mes-
senger RNA generated from this cis-acting transcription
mode would be transported to cytosol for protein expres-
sion. Due to the lack of newly synthesized NP and viral
polymerase, nascent cRNA generated from this cis-acting
mode might be rapidly degraded at the early time point
[7,9,33]. By contrast, during the mid- to late phase of
infection, the accumulations of cRNP and vRNP make the
viral polymerase complex has less chance to bind to the
ends from the same vRNA or cRNA template. At this stage,
the viral RNA polymerase is prone to utilize the vRNA/
cRNA ends derived from different templates from tran-
scription initiation (i.e. trans-activation mode). As the
polyadenylation of viral mRNA requires the viral
polymerase bind to the same viral template [12,29], tran-
scription initiated by the trans-activation mode would
favor viral RNA replication and further increase the vRNA
and cRNA levels. In our study, the mutated NS segment
could specifically enhance the NA vRNA and cRNA levels,
suggesting the trans-activation mode might require the 5'
and 3' vRNA ends derived from homologous RNA seg-
ments.
Detection of NA vRNA, cRNA and mRNA by primer exten- sion assays Figure 4
Detection of NA vRNA, cRNA and mRNA by primer exten-
sion assays. Total RNA from infected cells were harvested at 
8 and 24 hr postinfection. The reaction conditions were 
identical to previously described assays [31], except fluores-
cent vRNA-specific primer (5'-Cy3-TGGACTAGTGGGAG-
CATCAT-3') and cRNA/mRNA-specific primer (5'-Cy5-
TCCAGTATGGTTTTGATTTCCG-3') were used in the 
assays. The fluorescent products were resolved in 10% dena-
turing polyacrylamide gels and the images were analyzed by 
an imaging analyzer (Typhoon 8600 variable mode imager, 
Amersham Biosciences). Signals for the vRNA, cRNA and 
mRNA are shown as indicated. cRNA and vRNA signals of 
the NSNA-U were consistently higher than those of the All-
U in independent attempts (Trials 1 and 2).Virology Journal 2008, 5:2 http://www.virologyj.com/content/5/1/2
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In conclusion, our result demonstrated that the segment
specific regions have roles in controlling viral transcrip-
tion and replication. Viral RNA with compatible segment-
specific sequences might facilitate viral replication in
trans. Given the fact that different viral RNA segments
might have subtle sequence requirements for viral RNA
synthesis [34], further studies on the segment-specific
non-coding regions in other viral segments are needed.
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